---
figid: PMC5061805__BCP-82-1280-g002
figtitle: Mechanisms involved in the delay of therapeutic response to classic antidepressants
  in MDD patients
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
- Danio rerio
pmcid: PMC5061805
filename: BCP-82-1280-g002.jpg
figlink: /pmc/articles/PMC5061805/figure/bcp12845-fig-0002/
number: F2
caption: Mechanisms involved in the delay of therapeutic response to classic antidepressants
  in MDD patients. The classic antidepressants, which inhibit the re‐uptake of monoamines,
  increase the availability of serotonin, norepinephrine and dopamine in the synaptic
  cleft. The activation of serotonergic receptors (example above) triggers the internal
  cellular signalling that leads to CREB activity and BDNF transcription. The synthesis
  and release of BDNF from the transcription process activates TrkB receptors and
  downstream mTOR signalling pathway, which coincides with the therapeutic response.
  Activated mTOR triggers the translational machinery, increasing protein synthesis
  involved in synaptogenesis. Genetic polymorphisms of the serotonin transporter and
  BDNF are involved in resistance to classical antidepressant treatment in some people.
  These genetic traits may be at least one of the possible mechanisms related to refractory
  to classical treatments. MDD, major depressive disorder; 5‐HTTLPR, serotonin‐transporter‐linked
  polymorphic region; Val66met BDNF single‐nucleotide polymorphism; SSRI, selective
  serotonin re‐uptake inhibitors; SNRI, serotonin‐norepinephrine re‐uptake inhibitors;
  TCA, tricyclic antidepressants; BDNF, brain‐derived neurotrophic factor; TrkB, tropomyosin‐related
  kinase B receptor; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol‐3‐kinase;
  ERK, extracellular signal‐regulated kinase; MEK, mitogen‐activated protein kinase;
  Akt, protein kinase B (PKB); S6K, ribosomal protein S6 kinase; eEF2K, eukaryotic
  elongation factor‐2 kinase; 4E‐BP, eukaryotic initiation factor 4E (eIF4E)‐binding
  proteins; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; CREB, cAMP
  response element‐binding protein
papertitle: New perspectives on the involvement of mTOR in depression as well as in
  the action of antidepressant drugs.
reftext: Zuleide M. Ignácio, et al. Br J Clin Pharmacol. 2016 Nov;82(5):1280-1290.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9541656
figid_alias: PMC5061805__F2
figtype: Figure
redirect_from: /figures/PMC5061805__F2
ndex: e5cf369c-dee9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5061805__BCP-82-1280-g002.html
  '@type': Dataset
  description: Mechanisms involved in the delay of therapeutic response to classic
    antidepressants in MDD patients. The classic antidepressants, which inhibit the
    re‐uptake of monoamines, increase the availability of serotonin, norepinephrine
    and dopamine in the synaptic cleft. The activation of serotonergic receptors (example
    above) triggers the internal cellular signalling that leads to CREB activity and
    BDNF transcription. The synthesis and release of BDNF from the transcription process
    activates TrkB receptors and downstream mTOR signalling pathway, which coincides
    with the therapeutic response. Activated mTOR triggers the translational machinery,
    increasing protein synthesis involved in synaptogenesis. Genetic polymorphisms
    of the serotonin transporter and BDNF are involved in resistance to classical
    antidepressant treatment in some people. These genetic traits may be at least
    one of the possible mechanisms related to refractory to classical treatments.
    MDD, major depressive disorder; 5‐HTTLPR, serotonin‐transporter‐linked polymorphic
    region; Val66met BDNF single‐nucleotide polymorphism; SSRI, selective serotonin
    re‐uptake inhibitors; SNRI, serotonin‐norepinephrine re‐uptake inhibitors; TCA, tricyclic
    antidepressants; BDNF, brain‐derived neurotrophic factor; TrkB, tropomyosin‐related
    kinase B receptor; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol‐3‐kinase;
    ERK, extracellular signal‐regulated kinase; MEK, mitogen‐activated protein kinase;
    Akt, protein kinase B (PKB); S6K, ribosomal protein S6 kinase; eEF2K, eukaryotic
    elongation factor‐2 kinase; 4E‐BP, eukaryotic initiation factor 4E (eIF4E)‐binding
    proteins; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; CREB, cAMP
    response element‐binding protein
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - 5-HT1B
  - 5-HT1A
  - 5-HT2A
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Dsor1
  - Mtk
  - Akt
  - Erk7
  - rl
  - CrebB
  - CrebA
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - Mtor
  - Tor
  - S6k
  - Thor
  - SLC6A4
  - BDNF
  - BDNF-AS
  - NTRK2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - MTOR
  - RPS6KB1
  - EEF2K
  - bdnf
  - kita
  - ngfra
  - mtor
  - eif4ebp3l
  - eef2k
---
